Incontri oncologici Triveneto X Incontro Metastasi Cerebrali da Carcinoma Mammario HER2-positivo Negrar, 7 Ottobre 2014

RUOLO DELLA RADIOTERAPIA STEREOTASSICA /RADIOCHIRUGIA


Filippo Alongi Direttore UOC Radioterapia Oncologica



Ospedale
Sacro Cuore - Don Calabria
Negrar (Verona)



INTRODUCTION




- •Relapses in the CNS are common (>50%) and represent a barrier to cure patients with breast cancer.
- Less than 20 % of patients survived 1 year.

- •A further **increase in incidence of BM** is seen in breast cancers patients with:
- -estrogen receptor (ER) negative
- -HER2 positive.



SYSTEMIC TREATMENT

- •"Consensus guidelines" on systemic treatment after BM inHER2 positive breast cancer patients are lacking.
- •May be *Trastuzumab* is not able to cross the BBB
- •In fact, almost one-third of metastatic BC patients that receive *Trastuzumab* eventually will develop BM .



Brufsky AM et al, Clinical cancer research 2011

Duchnowska R, Oncologist 2012



PROGNOSTIC FACTORS

Table 1 Median survival duration according to RPA class for patient treated with WBRT


RPA class	Clinical characteristics	All tumors BM MS in m [32]	Breast BM MS in m [31]
1	KPS ≥70 and age <65 and controlled primary tumor and no extra cranial metastases	7.1	15
2	KPS ≥70 and age ≥65 or uncontrolled primary tumor or extra cranial metastases	4.2	11
3	KPS <70	2.3	3

MS median survival, m months, KPS Karnofsky performance status, BM brain metastases, WBRT whole-brain radiotherapy

•KPS <70,
• age >65,
•uncontrolled Primary,
•extracranial metastasis,
are "prognostic factors"
and....




Therapeutic ALGORITM





LOCAL TREATMENT FOR SINGLE/FEW MTS



Case of best prognostic factors:

•Surgery?

•SRS?

•Adding WBRT?

...No consensus!!!

Gil-Gil MG et al .Clin Trasl Oncol 2014




Surgery(plus WBRT) vs WBRT



A RANDOMIZED TRIAL OF SURGERY IN THE TREATMENT OF SINGLE METASTASES TO THE BRAIN

ROY A. PATCHELL, M.D., PHILLIP A. TIBBS, M.D., JOHN W. WALSH, M.D., ROBERT J. DEMPSEY, M.D., YOSH MARUYAMA, M.D., RICHARD J. KRYSCIO, Ph.D., WILLIAM R. MARKESBERY, M.D., JOHN S. MACDONALD, M.D., AND BYRON YOUNG, M.D.

- •Brain recurrence (BR) was less frequent in the surgical group than in the radiation alone group (20 vs 52 %; p>0.02).
- •Median OS was significantly longer in the surgical group than in the radiation group (40 vs 15 weeks; p<0.01).





Surgery (plus WBRT) vs WBRT

...Thus, Surgery (plus WBRT) is the best option??

•Operative mortality has to be weighed against any possible benefit from surgery. In earlier series of patients with single brain metastases who were treated with surgery, operative mortality rates were in the range of 10-34%

...What about SRS??



RADIOSURGERY

Stereotactic radiosurgery (SRS)


- "Stereo": "solid" or "3-dimensional"
- "Tact": (to touch)

Thus it means: "3 dimensional arrangement to touch"



Able to delivery:

"High doses to small volume with maximum surrounding organ sparing"



Isolated brain metastasis from Breast Ca.

Dose prescription: 25 Gy in single session (ICRU)



RADIOSURGERY FOR SINGLE/FEW BRAIN METS



Invasive





Non-Invasive







SRS

Radiosurgery is intended to provide:

- > local tumor control,
- improve clinical symptomatology,
- •enhance survival.

All of these radiosurgical goals are generally achieved with:

- low morbidity,
- low cost,
- essentially zero mortality

Noyes et al, Radiosurgery 1996; Rutigliano et al, Neurosurgery 1995



Surgery vs SRS

- **NO randomized trials** comparing surgical metastasectomy with SRS
- > Retrospective reports support comparable outcomes.
- •The SELECTION of treatment should depend on patient- and disease-related factors(SIR/RPA).



Surgery+WBRT vs SRS+WBRT

Several retrospective studies have compared S + WBRT with SRS + WBRT.


All of them reported no significant differences on OS or longer time to BR

(...except for one, that showed an improvement for S+WBRT, although probably there may have been a selection bias, since SRS patients were poor candidates for surgery. *Bindal AK et al, J Neurosurgery 1996*)



FRACTIONATED STEREOTACTIC RADIOSURGERY





Lesion diameter >3 cm <

3 FRACTIONS (>8 Gy per fraction)

2 FRACTIONS (> 11.5 Gy per fraction)

Wiggenraad R, et al. A systematic review. Radiother Oncol 2011



RADIOSURGERY FOR SINGLE/FEW BRAIN METS

WBRT has been routinely added to SRS for single/few mts... until this paper

Lancet Oncol 2009; 10: 1037-44

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial

Eric L Chang, Jeffrey S Wefel, Kenneth R Hess, Pamela K Allen, Frederick F Lang, David G Kornguth, Rebecca B Arbuckle, J Michael Swint, Almon S Shiu, Moshe H Maor, Christina A Meyers

Stereotactic radiosurgery	Stereotactic radiosurgery				
olus whole-brain	alone (N=20)				

p (A>B)

radiotherapy (N=11)						
Total recall	52%	24%	96%			
Delayed recall	22%	6%	86%			
Delayed recognition	11%	0%	86%			

p (A>B)=Bayesian probability that the proportion with a significant neurocognitive worsening is higher in stereotactic radiosurgery plus whole-brain radiotherapy than stereotactic radiosurgery alone.

WBRT could reduce neurcognition... But what about Outcome?

Brain metastases:

SRS vs SRS + WBRT randomized clinical trials

Randomized phase III trials in brain metastases

SRS vs SRS + WBRT:

	# of patients	Intracranial progression free survival (months)	Overall survival (months)
Aoyama 2006	132 (67 SRS vs 65 SRS+WBRT)		
Chang 2009	58 (30 SRS vs 28 SRS+ WBRT)	Favour to SRS + WBRT	No
Kocher & Soffietti 2010	359 (179 SRS/Surg. vs 180 SRS/Surg + WBRT)		difference
Mondschein 2010 (Abst ASTRO) MELANOMA	74 45 SRS vs 29 SRS+WBRT	2.1 vs 3 (p = 0.815)	

Courtesy of Dr. E. Waranzano, Terni



FRACTIONATED STEREOTACTIC RADIOSURGERY AND WHOLE BRAIN RADIOTHERAPY

Lancet Oncol 2009; 10: 1037-44

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial

Eric L Chang, Jeffrey S Wefel, Kenneth R Hess, Pamela K Allen, Frederick F Lang, David G Kornguth, Rebecca B Arbuckle, J Michael Swint, Almon S Shiu, Moshe H Maor, Christina A Meyers


- 1. WBRT causes a decline in learning and memory function by 4 months compared with the group that received SRS alone.
- 2. In patients 1-3 brain metastases initial treatment should be SRS
- 3. clinical close monitoring is recommended for early diagnosis of relapse
- 4. WBRT should be reserved only as a salvage therapy



RADIOSURGERY FOR SINGLE/FEW BRAIN METS


Patient with 2 brain metastases.

RADIOSURGERY: Dose prescription: 25 Gy in single fraction.





Only WBRT for more than 3??





Only WBRT for >3 mts??

Lancet Oncol 2014; 15: 387-95

Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study

•M&M: 1194 pts treated with SRS (1 \rightarrow 10 brain mets)

•RESULTS: Overall survival →1-5 BM= 5-10 BM




Figure: Kaplan-Meler curves of overall survival HR=hazard ratio.

Interpretation Our results suggest that stereotactic radiosurgery without WBRT in patients with five to ten brain metastases is non-inferior to that in patients with two to four brain metastases. Considering the minimal invasiveness of stereotactic radiosurgery and the fewer side-effects than with WBRT, stereotactic radiosurgery might be a suitable alternative for patients with up to ten brain metastases.



Only WBRT for >3 mts??

THE LANCET Oncology

Volume 15, Issue 7, June 2014, Pages e246-e247



Correspondence

Stereotactic radiosurgery for patients with brain metastases

Filippo Alongi^a, Alba Fiorentino^a, Marta Scorsetti^b

Available online 26 May 2014

..Despite the relevance of Yamamoto and colleagues' study, its messages need to be interpreted carefully. Oversimplification of oncological treatment should be avoided...

...Whole-brain radiotherapy is the standard treatment for non-oligometastatic patients.

Referred to by Masaaki Yamamoto, Toru Serizawa, Takashi Shuto, Atsuya Akabane, Yoshinori Higuchi, Jun Kawagishi, Kazuhiro Yamanaka, Yasunori Sato, Hidefumi Jokura

Stereotactic radiosurgery for patients with brain metastases – Authors' reply


^a Department of Radiation Oncology, Sacro Cuore Hospital, Negrar-Verona 37134, Italy

^b Department of Radiotherapy and Radiosurgery, Istituto Clinico Humanitas Cancer Center, Milano, Italy

^c Department of Neurosurgery, Istituto Clinico Humanitas Cancer Center, Milano, Italy



TAKE HOME MESSAGE



1)<u>SRS</u> should be considered a routine treatment owing to better neurocognitive outcomes and a lower risk of late adverse effects in limited BM (1-3)

2) Whole-brain radiotherapy is still the standard treatment for non-oligometastatic patients.



CONCLUSIONS

JOURNAL OF CLINICAL ONCOLOGY

REVIEW ARTICLE

Cranial Stereotactic Radiosurgery: Current Status of the Initial Paradigm Shifter

Jason P. Sheehan, Chun-Po Yen, Cheng-Chia Lee, and Jay S. Loeffler

...Although the concept of radiosurgery has been present for more than six decades, radiosurgery continues to be refined and expanded.

Thus, the paradigm shift is not yet complete.



